Key result
Oral anticoagulation for venous thromboembolism resulted in low overall rates of recurrent VTE (1.3 per 100 patient-years) and major haemorrhage (2.8 per 100 patient-years).
Why the study?
Does the quality of oral anticoagulant control affect the incidence of recurrent venous thromboembolism and haemorrhages in patients with venous thromboembolism?
RCT (n=1,124)
Randomized to different durations
Yes
Does the quality of oral anticoagulant control affect the incidence of recurrent venous thromboembolism and haemorrhages in patients with venous thromboembolism?
In patients with venous thromboembolism, oral anticoagulation managed across multiple Swedish hospitals achieved acceptable laboratory performance and low rates of recurrent VTE and major hemorrhage.
No takes yet. Share an insight, caveat, or question.
Supports oral anticoagulation for VTE with good control; extends RCT safety data to multi-center practice.
Sam Schulman (1994) conducted an RCT in Venous thromboembolism (n=1,124). Oral anticoagulation (different durations) was evaluated on Recurrent venous thromboembolism and haemorrhages requiring hospitalization or treatment with blood products or vitamin K. Oral anticoagulation for venous thromboembolism resulted in low overall rates of recurrent VTE (1.3 per 100 patient-years) and major haemorrhage (2.8 per 100 patient-years).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: